Play video
Company Profile

Founded in 2019, Symray Biopharma is a biotechnology company focused on the innovative R&D and clinical translation of antibody-based biologics. The company was recognized as a Shanghai “Specialized, Refined, Distinctive and Innovative” (SRDI) enterprise in 2022 and holds National High-Tech Enterprise status. Guided by clinical value, Symray leverages an antibody discovery platform covering all species, all epitopes and all functions, a high-throughput, automated antibody characterization platform, and a systematic, tailored drug validation platform to develop a series of therapeutic modalities, including monoclonal antibodies, bispecific antibodies, ADCs and antibody fusion proteins.

With the mission of “establishing a new paradigm for innovative biologics R&D”, Symray Biopharma is committed to connecting innovators across the pharmaceutical R&D value chain — offering scientists a platform for translational innovation and pharmaceutical companies with differentiated, high-quality pipelines. The company currently has 30+ pipeline programs, 200+ targets under development and 20+ external collaborations. A highly experienced R&D team, mature technology platforms and an extensive off-the-shelf product portfolio enable us to stand out in a highly competitive market.

5000m2
R&D site
50+
R&D team members
70%
MSc/PhD holders
200+
Targets under development
20+
External collaborations
Milestones
A high-tech enterprise dedicated to innovative R&D of antibody-based biologics
  • 2023
  • 2022
  • 2021
  • 2020
Management Team
Dr. Mingyao LiuFounder & Chairman
Management Team
Dr. Mingyao LiuFounder & Chairman
  • PhD in Cell Biology, University of Maryland, USA
  • Over 30 years of research on innovative drug mechanisms and translational medicine
  • Recipient of the National Science and Technology Progress Award, First Prize
  • Recipient of the Shanghai Science and Technology Progress Award, First Prize
  • PhD in Cell Biology, University of Maryland, USA
  • Over 30 years of research on innovative drug mechanisms and translational medicine
  • Recipient of the National Science and Technology Progress Award, First Prize
  • Recipient of the Shanghai Science and Technology Progress Award, First Prize